• What is VAXO-Q-RE?
VAXO-Q-RE is a product that is developed for autologous Adoptive Cellular Therapy. It consists of the basic players of innate and adaptive immunity. Briefly, macrophages and Natural Killer cells (innate immune cells) and activated Dendritic Cells, T cells and antibody producing plasma cells (adaptive immune cells).
Innate immune cells are ready to fight any pathogen or cancer cell in an antigen independent manner, while T cells and B cells require pre
activation with antigenic peptides. Activation of adaptive immune cells is performed with dendritic cells, a type of antigen presenting cells (APC). All those cells can be generated from patient’s blood and then be infused back to the patient.
• Action role of immune cells
Macrophages and Natural Killer cells can recognize and kill foreign pathogens and cancer cells. Macrophages are phagocytic cells and Natural Killer cells that have the ability to eliminate cancer cells in an MHC-independent manner. Cytotoxic T-cells (CTLs) are activated against specific antigens by dendritic cells and have the ability to target and kill cancer cells expressing the specific antigen. Antibodies produced by plasma cells, tag cancer cells and help their recognition by phagocytes or complement proteins leading to their subsequent destruction.
• RGCC’s Product
RGCCs laboratories use patients’ isolated peripheral blood mononuclear cells as a source for the in vitro production of VAXO-Q-RE. Macrophages and Natural Killer cells are selected and expanded in large numbers. Monocytes are used as a source for the production of DCs. DCs are then pulsed with synthesized peptides designed specifically to mount an immune response against tumor proteins. These peptides are selected carefully so as to activate both T
lymphocytes (CTLs) as well as antibody producing cells aiming at long term memory cells and overall protection. VAXO-Q-RE is composed of 2 doses, with one dose containing innate immune cells (macrophages and Natural Killer cells) and a second dose containing adaptive immune cells (CTLs and antibody producing cells). • Administration
VAXO-Q-RE needs to be administered in an effective way. Administration directions will be on a separate page. • Adverse events
VAXO-Q-RE is an autologous Adoptive Cellular Therapy and is generally a very safe procedure. Adverse events are mild and include flu-like symptoms (fever) and injection site reaction (skin rash). (Sanchez et al., 2021; Boudewijns et al. 2016; Zhang et al. 2015).
VAXO-Q-RE cell therapy is not recommended in the following cases:
– Chemo and radiotherapy – Suppression of the immune systems
– Recent Blood transfusions- must wait a minimum of 100-120 days after blood transfusion – Active autoimmune diseases